Why a fertility clinic uses ganirelix
Ganirelix blocks the signal from gonadotropin-releasing hormone (GnRH). This prevents an early surge of luteinizing hormone (LH), the signal that normally prompts an ovary to release an egg.
In studies summarized in the label, fewer than 1% of the 463 participants in the labeled-dose group had the hormone pattern defined as a premature LH surge. That measure describes the timing of ovulation. The chance of a live birth depends on the full cycle and individual factors.
Prescription details and safety
The labeled presentation is a 250 microgram per 0.5 mL prefilled syringe. The fertility team and pharmacy can confirm the product and the number of syringes needed for the cycle.
The label excludes use with known or suspected pregnancy or a known allergy to ganirelix, its ingredients or related medicines. Serious allergic reactions have been reported.